Accordingly, the IL-2R is therapeutically targeted in CTCL by denileukin diftitox, an engineered combination of IL-2 and Diphtheria toxin (Ontac) [5]. This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.